Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?

Supportive Care in Cancer

Volumn 13, Issue 8, 2005, Pages 647-651

  Argyriou, Andreas A ^a   Polychronopoulos, Panagiotis ^a   Koutras, Angelos ^a   Iconomou, Gregoris ^a   Iconomou, Alexander ^a   Kalofonos, Haralabos P ^a   Chroni, Elisabeth ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Cancer; Chemotherapy; Clinical evaluation; Neurotoxicity; Prediction

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; CISPLATIN; DRUG THERAPY, COMBINATION; FEMALE; FORECASTING; GREECE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROTOXINS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES;

EID: 22844448647     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0776-9     Document Type: Article

References (18)

1. Alberts DS, Noel JK (1995) Cisplatin-associated neurotoxicity: can it be prevented? Anti-cancer Drugs 6:369-383
2. Argyriou AA, Chroni E, Koutras A et al (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64(1):26-31
3. Berger T, Malayeri R, Doppelbauer G et al (1997) Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 33(9):1393-1399
4. Bolton CF, Gilbert JJ, Girvin JP et al (1979) Nerve and muscle biopsy. Electrophysiology and morphology in polyneuropathy. Neurology 29:354-362
5. Cavaletti G, Bogliun G, Marzorati L et al (2004) Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 15:1439-1442
6. Chaudhry V, Rowinsky EK, Sartorius SE et al (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35:304-311
7. Chaundhry V, Cornblath DR, Corse A et al (2002) Thalidomide-induced neuropathy. Neurology 59:1872-1875
8. Dyck PJ, Thomas PK (eds) (1993) Peripheral neuropathy, vol 2. (3rd edn.) WB Saunders, Philadelphia, PA, pp 1310-1317
9. Jann S, Bramerio MA, Beretta S et al (2003) Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 61 (11):1607-1610
10. Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle, principles and practice (3rd edn.). Oxford University Press, New York, pp 91-166
11. Lauria G, McArthur JC, Hauer PE et al (1998) Neuropathological alterations in diabetic truncal neuropathy: evaluation by skin biopsy. J Neurol Neurosurg Psychiatry 65(5):762-766
12. Lauria G, Pareyson D, Grisoli M et al (2000) Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol 47 (1):104-109
13. Lipton RB, Apfel SC, Dutcher JP et al (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39:368-373
14. Malik RA, Veves A, Walker D et al (2001) Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol 101 (4):367-374
15. McCarthy BG, Hsieh ST, Stocks A et al (1995) Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 45(10):1848-1855
16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
17. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
18. Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509-513